Publication of 2023 financial results and operating update
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival si…
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Clinical trial protocol approved in the US to initiate Phase 2 study with NOX-A12 in glioblastoma providing a clear road…
Cloud Subscription Annual Recurring Revenue (ARR) in the fourth quarter and full-year 2023 increased 37% year-over-year…
. Median overall survival surpasses 19 months and continues to improve in glioblastoma patients receiving NOX-A12 comb…
Substantially improved survival and progression-free survival under NOX-A12 treatment combination compared to matched st…
Subscription Annual Recurring Revenue (ARR) in the third quarter increased 15% year-over-year to $1.08 billion Cloud Su…